A1 Refereed original research article in a scientific journal

I-123-Labeled oxLDL Is Widely Distributed Throughout the Whole Body in Mice




AuthorsNakano A, Kawashima H, Miyake Y, Zeniya T, Yamamoto A, Koshino K, Temma T, Fukuda T, Fujita Y, Kakino A, Kanaya S, Sawamura T, Iida H

PublisherSPRINGER HEIDELBERG

Publication year2018

JournalNuclear Medicine and Molecular Imaging

Journal name in sourceNUCLEAR MEDICINE AND MOLECULAR IMAGING

Journal acronymNUCL MED MOLEC IMAG

Volume52

Issue2

First page 144

Last page153

Number of pages10

ISSN1869-3474

DOIhttps://doi.org/10.1007/s13139-017-0497-2


Abstract
Purpose Oxidized low-density lipoprotein (oxLDL) plays a key role in endothelial dysfunction, vascular inflammation, and atherogenesis. The aim of this study was to assess blood clearance and in vivo kinetics of radiolabeled oxLDL in mice.Methods We synthesized I-123-oxLDL by the iodine monochloride method, and performed an uptake study in CHO cells transfected with lectin-like oxLDL receptor-1 (LOX-1). In addition, we evaluated the consistency between the I-123-oxLDL autoradiogram and the fluorescence image of DiI-oxLDL after intravenous injection for both spleen and liver. Whole-body dynamic planar images were acquired 10 min post injection of I-123-oxLDL to generate regional time-activity curves (TACs) of the liver, heart, lungs, kidney, head, and abdomen. Regional radioactivity for those excised tissues as well as the bladder, stomach, gut, and thyroid were assessed using a gamma counter, yielding percent injected dose (%ID) and dose uptake ratio (DUR). The presence of I-123-oxLDL in serum was assessed by radio-HPLC.Results The cellular uptakes of I-123-oxLDL were identical to those of DiI-oxLDL, and autoradiograms and fluorescence images also exhibited consistent distributions. TACs after injection of I-123-oxLDL demonstrated extremely fast kinetics. The radioactivity uptake at 10 min post-injection was highest in the liver (40.8 +/- 2.4% ID). Notably, radioactivity uptake was equivalent throughout the rest of the body (39.4 +/- 2.7% ID). HPLC analysis revealed no remaining I-123-oxLDL or its metabolites in the blood.Conclusion I-123-OxLDL was widely distributed not only in the liver, but also throughout the whole body, providing insight into the pathophysiological effects of oxLDL.



Last updated on 2024-26-11 at 10:34